Zevra exits ADHD franchise, repays debt with $148M voucher sale and settlement proceeds

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read

Key Changes

• high

  Sold entire AZSTARYS/KP1077 portfolio to Commave for $43.3M gain, settling litigation and exiting CNS stimulant business to focus on rare metabolic diseases.

  MD&A: Commave Settlement verify on EDGAR →
• high

  Repaid $63M term loan in full using PRV sale proceeds ($148M net) and settlement cash, eliminating ~$2M quarterly interest expense and covenant restrictions.

  MD&A: Debt Repayment verify on EDGAR →
• high

  MIPLYFFA enrollments grew 39% year-over-year to 170 patients; Q1 revenue up 77% to $36.2M driven by commercial uptake and expanded European EAP.

  MD&A: MIPLYFFA Progress verify on EDGAR →